Sensitivity Assay of Resistant Escherichia coli to Fosfomycin, Kanamycin, Rifampicin, Ceftriaxone, Imipenem, and Vancomycin

Tina Rostinawati Rostinawati; Rikadianan rikadianan; Imam Adi Wicaksono

doi:10.24198/ijpst.v1i1.42856

Sensitivity Assay of Resistant Escherichia coli to Fosfomycin, Kanamycin, Rifampicin, Ceftriaxone, Imipenem, and Vancomycin

Tina Rostinawati Rostinawati, Rikadianan rikadianan, Imam Adi Wicaksono

Abstrak

Antibiotic resistance is a major global health problem and continues to increase, so there is a need for
better evaluation and therapeutic advice for Urinary Tract Infection (UTI) patients. It had isolated E. coli
from clinical isolates that were resistant to antibiotics of β-lactam, the first generation of cephalosporin
and fluoroquinolone. Characterization of bacterial sensitivity should be analyzed to other antibiotics
with different mechanisms. Therefore, this study aims to analyze the antibiotic activity of fosfomycin,
kanamycin, rifampicin, ceftriaxone, imipenem, and vancomycin against to resistant Escherichia coli
clinical isolates of UTI. The sensitivity test in this study used the Kirby-Bauer disc diffusion method
and data analysis using SPSS version 24. The results revealed the diameter of inhibition zone (mm) of
antibiotics of fosfomycin, ceftriaxone, imipenem, kanamycin, rifampicin, and vancomycin respectively
i.e. 38±1; 36.3±1.15; 35±1; 31.6±1,15; 28±1; and 26.3±0.17. Based on statistical analysis there were
significant differences in the activity of fosfomycin, ceftriaxone, imipenem, kanamycin, rifampicin,
and vancomycin.

Kata Kunci

clinical isolate, resistant E. coli, zone of inhibition diameter, activity, antibiotics.

Teks Lengkap:

PDF

Referensi

Wells BG, Dipiro JT, Schwinghammer TL, DiPiro C V. Pharmacoterapy A Phatophysiologic Approach. United State: McGraw-Hill Education. 2015. 1–4485 p.

Kementerian Kesehatan. Survey Demografi dan Kesehatan Indonesia. 2014;

Rajabnia-Chenari M, Gooran S, Fazeli F, Dashipourp A. Antibiotic Resistance Pattern in Urinary Tract infections in Imam-Ali Hospital, Zahedan (2010-2011). Zahedan J Res Med Sci J [Internet]. 2012;14(8):74–6. Available from: www.zjrms.ir

Syahputra RRI, Agustina D, Wahyudi SS. Pola Kepekaan Bakteri terhadap Antibiotik pada Pasien Infeksi Saluran Kemih di RSD DR. Soebandi Jember. J Agromedicine Med Sci. 2018;4(3):171–7.

Rostinawati T, Pamungkas TB, Moektiwardojo M, Subarnas A. ,Pola Resistensi Antibiotik Bakteri Penyebab Infeksi Saluran Kemih di Puskesmas Ibrahim Adjie Kota Bandung,. J Sains Farm Klin. 2021;8(1):27.

Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):103–20.

Bonkat G, Bartoletti R, Bruyere F, Cai T, Geerlings SE, Koves B, et al. EAU Guidelines on Urological Infections. Eur Assoc Urol 2021. 2021;(March):18–20.

Coyle EA PR. Urinary Tract Infections and Prostatitis. In: Pharmacotherapy: A Pathophysiologic Approach. 2017.

Yamamoto A, Yamasaki K. Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum β-lactamase producing (ESBL-) Escherichia coli: A comparison between meropenem and alternatives. Japanese J Geriatr. 2015;5(2):153–61.

Adil AS, Kundarto W. Evaluasi Penggunaan Antibiotik pada Pasien Geriatri Wanita Infeksi Saluran Kemih di Instalasi Rawat Inap RSUD Dr. Moewardi Surakarta Tahun 2017. JPSCR J Pharm Sci Clin Res. 2019;4(1):01.

Pontefract BA, Rovelsky SA, Madaras-Kelly KJ. Linezolid to treat urinary tract infections caused by vancomycin-resistant Enterococcus . SAGE Open Med. 2020;8:205031212097074.

Antonoplis A, Zang X, Wegner T, Wender PA, Cegelski L. Vancomycin-Arginine Conjugate Inhibits Growth of Carbapenem-Resistant E. coli and Targets Cell-Wall Synthesis. ACS Chem Biol. 2019;14(9):2065–70.

Oteo J, Delgado-Iribarren A, Vega D, Bautista V, Rodríguez MC, Velasco M, et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents. 2008;32(6):534–7.

(CLSI) C and LSI. Performance Standards for Antimicrobial Susceptibility Testing. Twenty-Fou. Wayne: CLSI Document M100-S24; 2014 p.

Nurmala N, Virgiandhy I, Andriani A, Liana DF. Resistensi dan Sensitivitas Bakteri terhadap Antibiotik di RSU dr. Soedarso Pontianak Tahun 2011-2013. eJournal Kedokt Indones. 2015;3(1):21–8.

Rajabnia, M., Gooran S., Fazeli, F., Dashiopur A. Antibiotic Resistence Pattern in Urinary Tract Infections In Imam-Ali Hospital Zahedan 2010- 2011. Zahedan J Res Med Sci. 2012;3(2):151–3.

Neville LF, Shalit I, Warn PA, Rendell JT. Vancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model. J Antimicrob Chemother. 2022;77(6):1706–9.

Linsenmeyer K, Strymish J, Weir S, Berg G, Brecher S, Gupta K. Activity of fosfomycin against extended-spectrum-β-lactamase-producing uropathogens in patients in the community and hospitalized patients. Antimicrob Agents Chemother. 2016;60(2):1134–6.

Park YS, Adams-Haduch JM, Shutt KA, Yarabinec DM, Johnson LE, Hingwe A, et al. Clinical and microbiologic characteristics of cephalosporin-resistant escherichia coli at three centers in the United States. Antimicrob Agents Chemother. 2012;56(4):1870–6.

Garza-Cervantes JA, Meza-Bustillos JF, Resendiz-Hernández H, Suárez-Cantú IA, Ortega-Rivera OA, Salinas E, et al. Re-sensitizing Ampicillin and Kanamycin-Resistant E. coli and S. aureus Using Synergistic Metal Micronutrients-Antibiotic Combinations. Front Bioeng Biotechnol. 2020;8(June):1–21.

Joshua M, Raymond M. Virulence factors and antibiotic resistance patterns of uropathogenic Escherichia coli. African J Microbiol Res. 2014;8(43):3678–86.

Cross J, Jacobs RF. Vancomycin-resistant enterococcal infections. Semin Pediatr Infect Dis. 1996;7(3):162–9.

Matthews PC, Barrett LK, Warren S, Stoesser N, Snelling M, Scarborough M, et al. Oral fosfomycin for treatment of urinary tract infection: A retrospective cohort study. BMC Infect Dis [Internet]. 2016;16(1):1–11. Available from: http://dx.doi.org/10.1186/s12879-016-1888-1

Information NC for B. PubChem Compound Summary for CID 5479530, Ceftriaxone. 2022.

Kuiper SG, Leegwater E, Wilms EB, van Nieuwkoop C. Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections. Expert Opin Pharmacother [Internet]. 2020;21(15):1805–11. Available from: https://doi.org/10.1080/14656566.2020.1790525

Albayrak A, Fakioǧlu DM, Şenol E. Meropenem, rifampicin and gentamicin combination therapy in a patient with complicated urinary tract infection caused by extreme drug-resistant P. aeruginosa. Eur J Hosp Pharm . 2020;27(2):121–2.

DOI: https://doi.org/10.24198/ijpst.v1i1.42856